Which patients should receive a 2-dose schedule of Trumenba (MenB-FHbp)?

Healthy adolescents who are not at increased risk for meningococcal B disease should receive 2 doses of Trumenba (MenB-FHbp) administered at 0 and 6 months. If the second dose is given at an interval of less than 6 months, a third dose should be given at least 4 months after the 2nd dose.

For people age 10 years and older at increased risk for meningococcal B disease, 3 doses of Trumenba should be administered at 0, 1–2, and 6 months. The 3-dose series should be used for all people with functional or anatomic asplenia, people with persistent complement component deficiency (an immune system disorder) or those who take a complement inhibitor (eculizumab [Soliris] or ravulizumab [Ultomiris]), microbiologists who work with meningococcal isolates in a laboratory, and people exposed during serogroup B outbreaks.